Glycine Sleep Mechanism

Reusable mechanism note for the glycine-induced sleep initiation pathway. Primary relevance: Glycine NAC Sleep Stack.

Core Concept

Glycine facilitates sleep onset via two distinct, additive mechanisms:

  1. Thermoregulatory peripheral vasodilation → core temperature drop → sleep transition
  2. Inhibitory neurotransmission at glycine receptors (GlyR) → neuronal hyperpolarization

Mechanism 1 — Thermoregulatory Peripheral Vasodilation

Pathway

Glycine → peripheral vasodilation (primarily extremities) → increased heat dissipation via skin → core body temperature decline → facilitation of the natural pre-sleep temperature nadir → sleep onset

Evidence

  • PMID-11774038 — Human study demonstrating glycine-induced peripheral vasodilation and core temperature reduction (Supported)
  • The “warm feet, cool core” phenomenon is a well-established physiological precursor to sleep onset in humans
  • Magnitude of temperature drop at 1–3 g oral glycine in sleep-specific contexts has not been precisely quantified (Gap)

Vitals Relevance

Core temperature decline is one of the most reliable physiological signals preceding sleep onset. Wearable skin temperature sensors (Oura ring, Whoop) detect extremity temperature shifts that reflect this peripheral vasodilation signal. However, the specific contribution of oral glycine to this signal above baseline nocturnal temperature decline has not been isolated in wearable studies.

Mechanism 2 — Inhibitory Glycine Receptor Neurotransmission

Pathway

Glycine → glycine receptors (GlyR) in brainstem and spinal cord → antagonism of NMDA/AMPA receptor activity → neuronal hyperpolarization → reduced CNS neuronal excitability → sleep-facilitating effect

Evidence

  • PMID-12453916 — Human glycine receptor pharmacology; GlyR activation produces inhibitory signals in brainstem and spinal cord (Supported)
  • Same receptor system targeted by ketamine (NMDA antagonism) — different site but convergent inhibitory effect
  • Whether this mechanism contributes meaningfully to sleep at 1–3 g oral glycine doses in humans is biologically plausible but not directly quantified (Contested)

Evidence Grade by Component

ComponentGradeSource
Glycine crosses BBB via SAT1/SNAT2SupportedPMID-17124091
CNS glycine levels rise after oral ingestionSupportedPMID-17124091
Functional sleep-relevant endpoint quantification at 1–3 g oralContestedPMID-17124091
Glycine GlyR activation in brainstem/spinal cordSupportedPMID-12453916
Glycine peripheral vasodilation + core temp dropSupportedPMID-11774038

Key Distinction: Initiation vs. Architecture

Glycine’s primary mechanism is sleep initiation — reducing the time to fall asleep. It does not have a well-characterized direct effect on sleep architecture (SWS/REM proportions). The PSG finding of increased SWS (PMID-22872576, Reported, n=9) is interesting but requires replication in a larger study before being treated as a reliable effect.

Comparison to Other Sleep Initiation Mechanisms

CompoundMechanismEvidence Strength
GlycineCore temp drop + GlyR inhibitionSupported (small RCTs, n≤30)
MelatoninMT1/MT2 receptor agonism; circadian phase shiftSupported (larger RCT base)
Z-drugsGABA-A receptor modulationConfirmed (strong RCT evidence)

Glycine’s advantage over Z-drugs is safety profile: no dependence, no withdrawal risk, no next-day sedation at appropriate doses. Its disadvantage is smaller effect size and weaker evidence base.

Vitals Wearable Considerations

  • Skin temperature: Glycine-induced peripheral vasodilation may produce a detectable nocturnal skin temperature rise (extremities) preceding core temperature decline — testable against baseline
  • HRV: Core temperature fluctuations can affect HRV independently of CNS sleep mechanisms; do not attribute HRV changes to glycine’s direct neurotransmission effect
  • SOL (sleep onset latency): The most direct wearable-accessible endpoint for glycine’s mechanism; compare 7-night averages pre/post initiation